ClinicalTrials.gg
CompletedNCT02820363Updated Aug 10, 2021

Study Evaluating CERAMENT™|G in Open Diaphyseal Tibial Fractures

An interventional study of CERAMENT|G and SOC treatment in Tibial Fracture, sponsored by BONESUPPORT AB. Completed at 31 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-08-10.

Sponsored by BONESUPPORT AB · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Jul 2021, 5 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
201
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies in Tibial Fractures with a site in United States — 15 open to participants now, 18 under way, 3 of them phase 3. Tibial Fractures · United States.

Enrollment
11th of 38
201 · median 53
Started
2017
the only one that year
No phase
27 of 50
10 open now
Registered
23rd of 50
by date

Among the 50 studies in Tibial Fractures with a site in United States, this one is the 11th largest by enrollment of the 38 interventional ones that give a count, is the only one that started in 2017, is one of 27 with no phase, and was the 23rd registered.

Tibial Fractures

136 studies on the registry are indexed under Tibial Fractures; 38 are open to participants now.

Browse Tibial Fractures studies →

Open to participants now

15 of the 50 studies in Tibial Fractures with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 27 Tibial Fractures studies recruiting now, 13 (48%) set no upper age limit and 7 (26%) stop at 75 or younger; 5 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Tibial Fractures with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate the safety and effectiveness of CERAMENT™\|G used in conjunction with standard-of-care treatment compared to standard-of-care treatment alone in the care of subjects with open fractures of the tibial diaphysis.

Read the detailed description

CERAMENT™\|G is a resorbable, gentamicin containing ceramic bone graft indicated to fill bony voids or gaps which are not intrinsic to the stability of the bony structure and where there is risk of bacterial contamination.

03

Conditions studied

  • Tibial Fracture

Keywords

  • wound
  • open fracture
  • fracture
  • tibial
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  1. Male or female 18-21 years of age with radiographic evidence on plain x-rays of proximal and distal tibial physeal closure, OR male or female 22-75 years of age
  2. Gustilo-Anderson Grade II, IIIA, or IIIB open tibial shaft fracture (with or without involvement of the tibial plateau or pilon/plafond) amenable to fixation with an intramedullary nail
  3. Bone loss at the fracture site must have a radiographic apparent bone gap (RABG) between 3 and 27.5 millimeters.
  4. of at least 1 year
  5. Patient is willing to provide , is geographically stable and able to comply with the required follow up visits, testing schedule and medication regimen
  6. Adequate soft tissue coverage at the fracture site (through primary closure or surgical reconstruction, including local and free soft tissue transfer)
  7. Definitive wound closure within 14 days of the initial injury
  8. Unilateral fracture, or, in the case of individually-qualifying bilateral open tibia fractures, the more severe of the bilateral fractures.

Patients will be excluded if ANY of the following conditions apply:

  1. Pregnant or breastfeeding women or planning on becoming pregnant during the period
  2. Patient is currently participating in an investigational drug or other device study or previously enrolled in this study
  3. Renal failure or documented chronic kidney disease with serum creatinine ≥3.5 mg/L or being treated with dialysis
  4. Known to aminoglycoside antibiotics, calcium sulfate or calcium hydroxyapatite
  5. Pre-existing calcium metabolism disorder
  6. Uncontrolled diabetes mellitus ( levels > 10%)
  7. A current endocrine or metabolic disorder known to affect osteogenesis (e.g., Paget's disease, renal osteodystrophy, hyperthyroidism, parathyroid hormone disorder, Ehler-Danlos syndrome, osteogenesis imperfecta)
  8. Neuromuscular disorders such as myasthenia gravis or Parkinson's disease
  9. Currently has untreated malignant neoplasm(s), or is currently undergoing radiation therapy or chemotherapy
  10. Previous history of osteomyelitis in the index limb
  11. Ipsilateral tibial plateau or pilon/plafond fractures requiring a reconstruction that interferes with or prohibits the use of an intramedullary nail to stabilize the tibial shaft fracture or, in the opinion of the investigator, the treatment and/or rehabilitation of such fracture(s) would substantially interfere with the treatment, rehabilitation or other requirements of open tibial shaft fractures enrolled under this protocol.
  12. Other ipsilateral lower extremity fracture(s) if, in the opinion of the investigator, the treatment and/or rehabilitation of such fracture(s) will substantially interfere with the treatment, rehabilitation or other requirements outlined in this protocol.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
201 participants (actual)

Study arms

  • Experimental
    Test

    Tibial fracture fixation with IM Nail. Apply CERAMENT™\|G applied to bony void(s).

    Device: CERAMENT|G · Procedure: SOC treatment

  • Active comparator
    Control

    Tibial fracture fixation with IM nail.

    Procedure: SOC treatment

Interventions

  • DeviceCERAMENT|G

    Surgical repair of tibia fracture, CERAMENT™\|G applied to bony voids.

  • ProcedureSOC treatment

    surgical repair of tibial fracture

06

What researchers measure

Primary outcomes

  1. Composite of absence of deep infection at fracture site, absence of secondary procedures intended to promote fracture union, and improvement in the SF-36v2 PCS.

    Absence of secondary procedures, absence of infection.

    Time frame: 12 months

  2. Serious device related adverse events

    for the test (CERAMENT™\|G) arm

    Time frame: 12 months

07

Study locations

31 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294-3409, United States
  • University of California
    Irvine, California 62697, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • Cedars Sinai Medical Orthopedic
    Los Angeles, California 90048, United States
  • Harbor-UCLA Medical Center
    Los Angeles, California 90509, United States
  • Denver Health Medical Center
    Denver, Colorado 80204, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • University of Kentucky
    Lexington, Kentucky 40536, United States
  • University of Missouri Health
    Columbia, Missouri 65212, United States
  • Washington University
    Saint Louis, Missouri 63110, United States
  • University of New Mexico
    Albuquerque, New Mexico 87106, United States
  • New York University, Bellevue Hospital
    New York, New York 10016, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267-0212, United States
  • Department of Orthopedics Greenville Health System
    Greenville, South Carolina 29605, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • University of Texas Health Science Center
    San Antonio, Texas 78229, United States
  • West Virginia University
    Morgantown, West Virginia 26506, United States
  • Klinikum Bayreuth
    Bayreuth, DE-95445, Germany
  • Essen University Hospital
    Essen, 45147, Germany
  • BG Hospital Ludwigshafen
    Ludwigshafen, 67071, Germany
  • Universitätsmedizin Mainz
    Mainz, Germany
  • Rechts der Isar Hospital
    Munich, 81675, Germany
  • LMU Munich
    Munich, Germany
  • Universitätsklinikum Regensburg
    Regensburg, Germany
  • Samodzielny Publiczny Wojewodzki Szpital
    Szczecin, 70-891, Poland
  • University Hospital Coventry
    Coventry, CV 2 2DX, United Kingdom
  • The Royal London Hospital
    London, E1BB, United Kingdom
  • King's College Hospital
    London, SE5 9R, United Kingdom
  • Imperial College
    London, United Kingdom
  • University Hospitals
    Manchester, M23 9LT, United Kingdom
  • Southampton General Hospital
    Southampton, SO16 6YD, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Jul 2021, 53 months.

Of 39 interventional studies with no phase under Tibial Fractures, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 80. This study's 53 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2016
First posted
Jul 1, 2016
StartActual
Feb 14, 2017
Primary completionActual
Jul 31, 2021
CompletionActual
Jul 31, 2021
Last update
Aug 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02820363
Lead sponsor
BONESUPPORT AB
Responsible party
Sponsor
First posted
Jul 1, 2016
Start date
Feb 14, 2017
Primary completion
Jul 31, 2021
Completion
Jul 31, 2021
Last update
Aug 10, 2021

Study contacts

Douglas R. Dirschl, MD
principal investigator · The University of Chicago Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion